Drug Trial Radar · NCT07708961
Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Aug 28, 2026
Primary completion
Aug 31, 2036
Study completion Aug 31, 2036
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial compares the effect of adding WSD0922-FU to temozolomide versus temozolomide alone in slowing disease progression in patients with Epidermal Growth Factor Receptor (EGFR)-mutant, IDH-wildtype glioblastoma. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. WSD0922-FU is a targeted treatment which blocks EGFR. It is able to get into the brain and spinal cord and help treat those types of tumors. Adding WSD0922-FU to the usual treatment with temozolomide may be more effective in slowing disease progression, compared to temozolomide alone, in patients with EGFR-mutant, IDH-wildtype glioblastoma.
Conditions
- Glioblastoma, IDH-Wildtype
Interventions
Archive Sample RetrievalProcedure
Archived tumor specimens will be retrieved if available from original surgery for glioblastoma.
Biospecimen CollectionProcedure
Undergo collection of blood, cerebrospinal fluid (CSF), and/or tumor tissue samples
Chest RadiographyProcedure
Undergo chest x-ray
Echocardiography TestProcedure
Undergo ECHO
EGFR/EGFRvIII Inhibitor WSD0922-FUDrug
Given PO
Magnetic Resonance ImagingProcedure
Undergo brain MRI
TemozolomideDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Up to 5 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Arizona
Scottsdale, Arizona · Recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.